<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3237">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01991301</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-12-9997-AN-CTIL</org_study_id>
    <nct_id>NCT01991301</nct_id>
  </id_info>
  <brief_title>Carfilzomib for the Prevention of Graft Versus Host Disease</brief_title>
  <official_title>The Safety and Efficacy of Carfilzomib -a Novel Proteasome Inhibitor- for the Prevention of Acute Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety and efficacy of Carfilzumib, which is a
      novel biological agent used in the treatment of multiple myeloma in preventing
      graft-versus-host disease, after stem cells transplantation from unrelated donors.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>incidence of acute graft-versus host disease</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>We will evaluate the incidence of acute GVHD, grading and organ involvementBY STANDARD INTERNATIONAL CRITERIA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of chronic graft-versus-host disease</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>We will evaluate the progression of acute graft-versus-host disease to chronic graft-versus-host disease and the grading and organ involvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival rate</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>We will evaluate overall and disease-free survival after stem cell transplantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>carfilzumib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carfilzomib at a dose of 20mg/m2 I.V.  will be administrated at day 1, 2 post infusion of the stem cell (SC) graft to the first 10 patients. If no &gt; grade II toxicity* the next 10 patients will receive Carfilzomib (27 mg/m2) at day 1,2 and 8, 9, 15 and 16. If no &gt; grade II toxicity*  the next 10 patients will receive 2-3 cycles of Carfilzomib (27 mg/m2) administered at day 1,2 8,9,15 and 16 post SC graft infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carfilzumib</intervention_name>
    <description>carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease.</description>
    <arm_group_label>carfilzumib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with MDS/AML

          2. 18 years or older and willing and able to comply with the protocol requirements.

          3. LVEF â‰¥ 40%. 2-D transthoracic echocardiogram (ECHO) is the preferred method of
             evaluation. Multigated Acquisition Scan (MUGA) is acceptable if ECHO is not
             available.

          4. Patients undergoing 8-10/10 HLA matched unrelated and unmanipulated PBSC
             transplantation

          5. Patients conditioned with reduced intensity or reduced toxicity conditioning i.e.
             Fludarabine combine with Treosulfan or 2-4 days of I.V Busulfan.

          6. Patients must sign written informed consent.

          7. Adequate birth control in fertile patients.

        Exclusion Criteria:

          1. Patients undergoing other type of transplantation or with other type of basic disease
             other than AML or MDS.

          2. Patients with respiratory failure (DLCO &lt; 30%).

          3. Active congestive heart failure (New York Heart Association [NYHA] Class III to IV),
             symptomatic ischemia, or conduction abnormalities uncontrolled by conventional
             intervention.

          4. Patients with &gt; grade II liver renal toxicity.

          5. Psychiatric conditions/disease that impair the ability to give informed consent or to
             adequately co-operate

          6. Bilirubin   &gt; 3.0 mg/dl, transaminases &gt; 3 times upper normal limit

          7. Creatinine &gt; 2.0 mg/dl

          8. ECOG-Performance status &gt; 2

          9. Uncontrolled infection

         10. Pregnancy or lactation

         11. CNS disease involvement

         12. Pleural effusion or ascites &gt; 1 liter.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Nagler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnon Nagler, MD</last_name>
    <phone>972 3 530 5830</phone>
    <email>a.nagler@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Avichai Shimoni, MD</last_name>
    <phone>972 3 530 5830</phone>
    <email>ashimoni@sheba.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnon Nagler, MD</last_name>
      <phone>972 3 530 5830</phone>
      <email>a.nagler@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Avichai Shimoni, MD</last_name>
      <phone>972 3 530 5830</phone>
      <email>ashimoni@sheba.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Arnon Nagler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 18, 2013</lastchanged_date>
  <firstreceived_date>November 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>graft-versus-host disease</keyword>
  <keyword>stem cell transplantation</keyword>
  <keyword>matched unrelated donors</keyword>
  <keyword>proteosmoe inhibitor</keyword>
  <keyword>carfilzumib</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
